FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311732425> ?p ?o ?g. }

• W4311732425 abstract "Abstract Background Lefamulin is a novel pleuromutilin protein synthesis inhibitor approved in the US, Canada, and Europe for the oral and intravenous treatment of community-acquired bacterial pneumonia (CABP) in adults due to typical and atypical pathogens. This study evaluated the in vitro activity of lefamulin and comparators against bacterial isolates from patients with community-acquired respiratory tract infections and hospitalized patients with pneumonia in the US and Latin America. Methods 1,907 unique isolates were collected within the SENTRY surveillance program from 29 medical centers in the US and 8 medical centers in Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Panama). Isolates were susceptibility tested by CLSI reference broth microdilution methods. CLSI breakpoints (M100, 2022) were applied. Results Lefamulin inhibited 100% of S. pneumoniae isolates at or below its susceptible (S) breakpoint of ≤ 0.5 mg/L, regardless of resistance to other antibiotics used to treat CABP (MIC90 values of 0.12 or 0.25 mg/L, Table). The penicillin-resistant (R; 12.7%), azithromycin-R (43.7%), and tetracycline-R S. pneumoniae (20.4%) displayed reduced susceptibility to the other CABP drugs tested, except moxifloxacin ( &gt; 98.2% S) and lefamulin (100% S). Lefamulin was highly potent against S. aureus, including MRSA, azithromycin-R, and moxifloxacin-R isolates, with 100% of isolates inhibited at or below the lefamulin S breakpoint of ≤ 0.25 mg/L. Susceptibility to azithromycin and moxifloxacin was particularly low for MRSA (13.9% and 25.0%, respectively). The fastidious Gram-negative H. influenzae and M. catarrhalis, of which 24.0% and 98.8%, respectively, were ß-lactamase positive, were S to lefamulin ( &gt; 93%) and the other tested CABP drugs ( &gt; 89%). Table. Susceptibility of pneumonia pathogens from US and Latin America to lefamulin and other CABP drugs Conclusion Lefamulin displayed potent in vitro activity against contemporary CABP pathogens from the US and Latin America. Its activity was unaffected by resistance to other antibiotic classes, including fluoroquinolones, macrolides, β-lactams, and tetracyclines. Lefamulin represents a valuable empiric treatment option for ambulatory and hospitalized patients with CABP, particularly when the causative pathogen is not identified or in settings with high prevalence of resistance. Disclosures Susanne Paukner, PhD, Nabriva Therapeutics: Inventor|Nabriva Therapeutics: Employee|Nabriva Therapeutics: Stocks/Bonds SJ Ryan Arends, PhD, AbbVie: Grant/Research Support|GSK: Grant/Research Support|Nabriva Therapeutics: Grant/Research Support|Shionogi: Grant/Research Support Rodrigo E. Mendes, PhD, AbbVie: Grant/Research Support|Cidara: Grant/Research Support|GSK: Grant/Research Support|Melinta: Grant/Research Support|Nabriva Therapeutics: Grant/Research Support|Office for Assistant Secretary of Defense for Health Affairs: Grant/Research Support|Pfizer: Grant/Research Support|Shionogi: Grant/Research Support|Spero Therapeutics: Grant/Research Support Steven P. Gelone, PharmD, Nabriva Therapeutics: Board Member|Nabriva Therapeutics: Inventor|Nabriva Therapeutics: Employee|Nabriva Therapeutics: Stocks/Bonds|Nabriva Therapeutics: Stocks/Bonds Helio S. Sader, MD, PhD, AbbVie: Grant/Research Support|Cidara: Grant/Research Support|Melinta: Grant/Research Support|Nabriva Therapeutics: Grant/Research Support|Pfizer: Grant/Research Support." @default.
• W4311732425 created "2022-12-28" @default.
• W4311732425 creator A5041157580 @default.
• W4311732425 creator A5063276526 @default.
• W4311732425 creator A5079280828 @default.
• W4311732425 creator A5086958262 @default.
• W4311732425 creator A5089371529 @default.
• W4311732425 date "2022-12-01" @default.
• W4311732425 modified "2023-10-17" @default.
• W4311732425 title "1689. <i>In Vitro</i> Activity of Lefamulin Against Bacterial Pathogens Collected From Pneumonia Patients in United States and Latin America Medical Centers in 2020-2021" @default.
• W4311732425 doi "https://doi.org/10.1093/ofid/ofac492.1319" @default.
• W4311732425 hasPublicationYear "2022" @default.
• W4311732425 type Work @default.
• W4311732425 citedByCount "0" @default.
• W4311732425 crossrefType "journal-article" @default.
• W4311732425 hasAuthorship W4311732425A5041157580 @default.
• W4311732425 hasAuthorship W4311732425A5063276526 @default.
• W4311732425 hasAuthorship W4311732425A5079280828 @default.
• W4311732425 hasAuthorship W4311732425A5086958262 @default.
• W4311732425 hasAuthorship W4311732425A5089371529 @default.
• W4311732425 hasBestOaLocation W43117324251 @default.
• W4311732425 hasConcept C126322002 @default.
• W4311732425 hasConcept C159047783 @default.
• W4311732425 hasConcept C176947019 @default.
• W4311732425 hasConcept C2776345407 @default.
• W4311732425 hasConcept C2777914695 @default.
• W4311732425 hasConcept C2778836808 @default.
• W4311732425 hasConcept C2778907293 @default.
• W4311732425 hasConcept C2778980435 @default.
• W4311732425 hasConcept C2779489039 @default.
• W4311732425 hasConcept C2780950330 @default.
• W4311732425 hasConcept C2781253189 @default.
• W4311732425 hasConcept C2781414143 @default.
• W4311732425 hasConcept C501593827 @default.
• W4311732425 hasConcept C523546767 @default.
• W4311732425 hasConcept C54355233 @default.
• W4311732425 hasConcept C71924100 @default.
• W4311732425 hasConcept C86803240 @default.
• W4311732425 hasConcept C89423630 @default.
• W4311732425 hasConceptScore W4311732425C126322002 @default.
• W4311732425 hasConceptScore W4311732425C159047783 @default.
• W4311732425 hasConceptScore W4311732425C176947019 @default.
• W4311732425 hasConceptScore W4311732425C2776345407 @default.
• W4311732425 hasConceptScore W4311732425C2777914695 @default.
• W4311732425 hasConceptScore W4311732425C2778836808 @default.
• W4311732425 hasConceptScore W4311732425C2778907293 @default.
• W4311732425 hasConceptScore W4311732425C2778980435 @default.
• W4311732425 hasConceptScore W4311732425C2779489039 @default.
• W4311732425 hasConceptScore W4311732425C2780950330 @default.
• W4311732425 hasConceptScore W4311732425C2781253189 @default.
• W4311732425 hasConceptScore W4311732425C2781414143 @default.
• W4311732425 hasConceptScore W4311732425C501593827 @default.
• W4311732425 hasConceptScore W4311732425C523546767 @default.
• W4311732425 hasConceptScore W4311732425C54355233 @default.
• W4311732425 hasConceptScore W4311732425C71924100 @default.
• W4311732425 hasConceptScore W4311732425C86803240 @default.
• W4311732425 hasConceptScore W4311732425C89423630 @default.
• W4311732425 hasIssue "Supplement_2" @default.
• W4311732425 hasLocation W43117324251 @default.
• W4311732425 hasOpenAccess W4311732425 @default.
• W4311732425 hasPrimaryLocation W43117324251 @default.
• W4311732425 hasRelatedWork W1967933806 @default.
• W4311732425 hasRelatedWork W2018382434 @default.
• W4311732425 hasRelatedWork W2065733068 @default.
• W4311732425 hasRelatedWork W2134756632 @default.
• W4311732425 hasRelatedWork W2794153158 @default.
• W4311732425 hasRelatedWork W2897265074 @default.
• W4311732425 hasRelatedWork W2915778969 @default.
• W4311732425 hasRelatedWork W3100231740 @default.
• W4311732425 hasRelatedWork W3195958508 @default.
• W4311732425 hasRelatedWork W4311732425 @default.
• W4311732425 hasVolume "9" @default.
• W4311732425 isParatext "false" @default.
• W4311732425 isRetracted "false" @default.
• W4311732425 workType "article" @default.